NASDAQ:MYGN Myriad Genetics (MYGN) Stock Forecast, Price & News $16.12 -0.67 (-3.99%) (As of 01:28 PM ET) Add Compare Share Share Today's Range$15.66▼$17.1450-Day Range$15.99▼$23.0852-Week Range$13.92▼$24.21Volume521,973 shsAverage Volume563,689 shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$24.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Myriad Genetics MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside49.6% Upside$24.20 Price TargetShort InterestBearish5.94% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.17Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.61) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector666th out of 972 stocksDiagnostic Substances Industry9th out of 13 stocks 3.1 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.20, Myriad Genetics has a forecasted upside of 49.6% from its current price of $16.18.Amount of Analyst CoverageMyriad Genetics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.94% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Myriad Genetics has recently increased by 8.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 2.3 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Myriad Genetics this week, compared to 3 articles on an average week.Search Interest1 people have searched for MYGN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.61) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Myriad Genetics (NASDAQ:MYGN) StockMyriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.Read More MYGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYGN Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comBrokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target at $24.20September 28, 2023 | finance.yahoo.comBREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOODSeptember 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. September 28, 2023 | finance.yahoo.comNew Myriad Genetics Survey Shows Breast Cancer Risk Factors Are MisunderstoodSeptember 23, 2023 | americanbankingnews.comQ1 2024 EPS Estimates for Myriad Genetics, Inc. Reduced by Leerink Partnrs (NASDAQ:MYGN)September 21, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Sell Rating on Myriad Genetics (MYGN)September 19, 2023 | finance.yahoo.comMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical TrialsSeptember 19, 2023 | finance.yahoo.comMyriad Genetics Issues 2022 Environmental, Social and Governance ReportSeptember 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. September 18, 2023 | finance.yahoo.comMyriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast CancerSeptember 8, 2023 | finance.yahoo.comIs Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapSeptember 8, 2023 | seekingalpha.comMyriad Genetics: FRα Addition Further Diversifies PortfolioSeptember 7, 2023 | finance.yahoo.comWhy Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?September 6, 2023 | finance.yahoo.comMyriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To WorkSeptember 6, 2023 | finance.yahoo.comNew Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of WomenSeptember 5, 2023 | finance.yahoo.comMyriad Genetics to Participate in Morgan Stanley Global Healthcare ConferenceAugust 22, 2023 | finance.yahoo.comMyriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer RiskAugust 17, 2023 | finance.yahoo.comMyriad Genetics to Host Investor Day on September 19, 2023August 16, 2023 | msn.comMyriad Genetics (MYGN) Adds ARR to Prolaris Biomarker TestAugust 15, 2023 | finance.yahoo.comMyriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®August 8, 2023 | msn.comJP Morgan Maintains Myriad Genetics (MYGN) Underweight RecommendationAugust 8, 2023 | finance.yahoo.comMyriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer TreatmentAugust 8, 2023 | finance.yahoo.comMyriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking StatusAugust 8, 2023 | finance.yahoo.comMyriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 LossAugust 8, 2023 | finance.yahoo.comMyriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking StatusAugust 5, 2023 | seekingalpha.comMyriad Genetics Non-GAAP EPS of -$0.08 beats by $0.01, revenue of $183.5M misses by $3.36MAugust 5, 2023 | finance.yahoo.comMyriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Earnings Call TranscriptSee More Headlines Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Company Calendar Last Earnings8/03/2023Today9/29/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,600Year Founded1991Price Target and Rating Average Stock Price Forecast$24.20 High Stock Price Forecast$28.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+44.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,000,000.00 Net Margins-35.51% Pretax Margin-37.92% Return on Equity-9.43% Return on Assets-6.67% Debt Debt-to-Equity Ratio0.05 Current Ratio1.33 Quick Ratio1.23 Sales & Book Value Annual Sales$678.40 million Price / Sales2.03 Cash Flow$0.20 per share Price / Cash Flow83.39 Book Value$10.93 per share Price / Book1.54Miscellaneous Outstanding Shares81,880,000Free Float80,245,000Market Cap$1.37 billion OptionableOptionable Beta1.78 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Paul J. Diaz (Age 61)CEO, Pres & Director Comp: $1.88MMr. R. Bryan Riggsbee (Age 52)Exec. VP, CFO & Treasurer Comp: $845.15kMs. Nicole Lambert (Age 49)Chief Operating Officer Comp: $746.91kDr. Kevin Richard Haas Ph.D. (Age 37)Chief Technology Officer Comp: $580.36kMr. Mark S. Verratti (Age 55)Chief Commercial Officer Comp: $794.85kMs. Natalie Munk (Age 42)Principal Accounting Officer Dr. Dale Muzzey Ph.D. (Age 43)Chief Scientific Officer Mr. Matthew ScaloSr. VP of Investor RelationsDr. Clivetty MartinezChief Compliance OfficerMs. Pamela Wong (Age 55)Chief Legal Officer More ExecutivesKey CompetitorsCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLANeogenNASDAQ:NEOGLantheusNASDAQ:LNTHQuidelOrthoNASDAQ:QDELView All CompetitorsInsiders & InstitutionsComerica BankBought 96,838 shares on 8/22/2023Ownership: 0.118%California State Teachers Retirement SystemSold 2,145 shares on 8/21/2023Ownership: 0.120%Teachers Retirement System of The State of KentuckyBought 1,416 shares on 8/21/2023Ownership: 0.032%Nuveen Asset Management LLCBought 275,802 shares on 8/16/2023Ownership: 0.606%State of Tennessee Treasury DepartmentBought 1,008 shares on 8/15/2023Ownership: 0.060%View All Insider TransactionsView All Institutional Transactions MYGN Stock - Frequently Asked Questions Should I buy or sell Myriad Genetics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares. View MYGN analyst ratings or view top-rated stocks. What is Myriad Genetics' stock price forecast for 2023? 5 brokers have issued 1 year target prices for Myriad Genetics' shares. Their MYGN share price forecasts range from $17.00 to $28.00. On average, they predict the company's stock price to reach $24.20 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts. How have MYGN shares performed in 2023? Myriad Genetics' stock was trading at $14.51 on January 1st, 2023. Since then, MYGN stock has increased by 15.7% and is now trading at $16.79. View the best growth stocks for 2023 here. When is Myriad Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our MYGN earnings forecast. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) released its earnings results on Thursday, August, 3rd. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $183.50 million for the quarter, compared to analyst estimates of $187.16 million. Myriad Genetics had a negative net margin of 35.51% and a negative trailing twelve-month return on equity of 9.43%. The business's revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.06) EPS. What ETFs hold Myriad Genetics' stock? ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).SPDR S&P 600 Small Cap ETF (SLY). What guidance has Myriad Genetics issued on next quarter's earnings? Myriad Genetics issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of -$0.36--$0.24 for the period, compared to the consensus EPS estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate of $742.12 million. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS). What is Myriad Genetics' stock symbol? Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN." How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Myriad Genetics' stock price today? One share of MYGN stock can currently be purchased for approximately $16.79. How much money does Myriad Genetics make? Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.37 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. How many employees does Myriad Genetics have? The company employs 2,600 workers across the globe. Does Myriad Genetics have any subsidiaries? The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.Read More How can I contact Myriad Genetics? Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640. This page (NASDAQ:MYGN) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.